IRIS
BODINI, GIORGIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.899
Totale 7.899
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 7.899
Totale 7.899
Salva come PNG Salva come JPEG
Città #
Genova 5.160
Genoa 1.023
Vado Ligure 928
Rapallo 771
Bordighera 17
Totale 7.899
Salva come PNG Salva come JPEG
Nome #
Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. 169
Proton pump inhibitors: use and misuse in the clinical setting 151
Advancements in the use of manometry and impedance testing for esophageal functional disorders 145
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index 142
Letter: Biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease 133
A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD) 133
A safety review of proton pump inhibitors to treat acid-related digestive diseases 133
Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma 129
Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. 129
Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease 128
Adalimumab trough levels and response to biological treatment in patients with Inflammatory Bowel Disease: a useful cut-off In clinical practice. 123
A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients 123
High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease 122
Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. 120
The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. 120
Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. 120
Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn’s disease. 119
Anti-TNF Antibodies For Prevention of Crohn's Disease Recurrence After Surgery: More Than An Hope. 118
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. 118
Tryciclic Antidepressants in Refractory GERD: Poorly Effective Drugs or Wrong Patients? 116
The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin 113
A Nodule, is a Nodule, is a Nodule: May Alpha-fetoprotein Make the Difference? 112
Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: the perfect storm 109
Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. 108
Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: Which implications in patients with Crohn's disease? 107
Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations 107
Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases 106
Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations 105
Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. 104
Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease. 103
The natural history of gastro-esophageal reflux disease: A comprehensive review 103
The appropriate use of proton-pump inhibitors 103
Optimal management of constipation associated with irritable bowel syndrome. 102
Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients 101
Epidemiology and natural history of gastroesophageal reflux disease 98
Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value? 97
Impedance-detected symptom association and number of reflux episodes as pre-treatment parameters that predict outcomes of gastroesophageal reflux disease patients 96
Esophageal motility abnormalities in gastroesophageal reflux disease 96
Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease 93
Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study 92
High-resolution manometry is superior to endoscopy and radiology in assessing and grading sliding hiatal hernia: A comparison with surgical in vivo evaluation 92
NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis 91
Prevention of Crohn's disease recurrence after surgery: on the road to recovery. 90
Gastrointestinal involvement in systemic sclerosis 90
Esophageal testing: What we have so far 89
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals 89
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications 89
A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease 89
Vegetal and animal food proteins have a different impact in the first postprandial hour of impedance-pH analysis in patients with heartburn 88
Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn's Disease 87
Reproducibility and transportability of the absence of incremental infectious adverse events in patients with higher anti-TNF drug levels 86
Treatment of early stage chronic hepatitis C virus infection 85
Regression of Fibrosis After DAAs Treatment of Patients with HCV Cirrhosis: Transposability to Non-Decompensated Patients 85
Active pharmacovigilance program in patients affected by psoriasis and inflammatory bowel diseases
 85
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 83
Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis 83
Letter: Biological therapies are effective for prevention of post-operative Crohn's disease recurrence 82
Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered 81
Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand 77
Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data 77
M01822 Diagnostic accuracy and Inter/Intra-observer Agreement between endoscopists with different expertise, before and after a short training, for the detection of gastric intestinal metaplasia by means of narrow band imaging with magnifying endoscopy 74
Course of oesophageal varices and performance of non-invasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease 73
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation 72
DEVELOPMENT AND VALIDATION OF A TEST TO MONITOR ENDOSCOPIC ACTIVITY IN PATIENTS WITH CROHN'S DISEASE BASED ON SERUM LEVELS OF PROTEINS 72
Concerns related to COVID-19 pandemic among patients with Inflammatory Bowel Disease, and its influence on patients management 71
Applicability of Parameters for the Non-Invasive Diagnosis of Esophageal Varices Needing Treatment to Cured HCV Patients 70
The Lyon Consensus: Does it differ from the previous ones? 68
Prevention of postoperative recurrence of Crohn's disease by Adalimumab: a case series. 67
Vonoprazan fumarate for the management of acid-related diseases 66
Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio 61
Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV 60
Intra- and interobserver Agreement between endoscopists and pathologists for detection of gastric intestinal metaplasia by means of narrow band imaging with magnifying endoscopy 59
Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice 57
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? 57
Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques 53
Prospective evaluation on the prevalence of serrated adenoma during a two-year period in an italian endoscopy centre 52
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD 46
Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease? 45
Elevated adherence to vaccination against SARS-CoV-2 among patients with Inflammatory Bowel Disease 43
Granulocytes and monocytes apheresis induces upregulation of TGFβ1 in patients with active ulcerative colitis: A possible involvement of soluble HLA-I 43
Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment 40
Association between esophageal motor disorders and pulmonary involvement in patients affected by systemic sclerosis: a retrospective study 38
Institution of an interdisciplinary IBD centre is associated with improved healthcare utilisation 34
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey 33
Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice 32
Letter: predictive factors for treatment discontinuation in IBD—anti-TNF trough levels and anti-drug antibodies 31
Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose 30
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 30
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 28
Crushed corticosteroid tablets in peristomal pyoderma gangrenosum: A case report 28
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study 24
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator 24
Clopidogrel-Induced Eosinophilic Colitis 23
Study on the impact of sexually transmitted infections on Quality of Life, mood and sexual function 22
Are Small Molecules Effective in Treating Inflammatory Pouch Disorders Following Ileal Pouch-Anal Anastomosis for Ulcerative Colitis? Here Is Where We Stand 22
Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study 22
Applying Lyon consensus criteria in the work‐up of patients with extra‐oesophageal symptoms – A multicentre retrospective study 21
Colorectal Cancer in Inflammatory Bowel Diseases: Epidemiology and Prevention: A Review 20
Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 19
Food Intolerances, Food Allergies and IBS: Lights and Shadows 19
Totale 8.113
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.564
article - articoli 30.564
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.128
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.695 0 0 0 0 0 273 329 205 232 374 204 78
2020/2021938 52 90 61 134 52 66 40 133 65 110 52 83
2021/20221.033 72 34 53 83 35 114 38 238 79 117 51 119
2022/2023963 111 100 14 64 155 118 7 84 166 7 121 16
2023/2024804 28 80 12 106 72 144 64 29 31 35 73 130
2024/20251.030 106 145 116 132 302 229 0 0 0 0 0 0
Totale 8.271